Cellectis (CLLS)
(Delayed Data from NSDQ)
$3.44 USD
+0.28 (8.86%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.42 -0.02 (-0.58%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLLS 3.44 +0.28(8.86%)
Will CLLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLLS
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't?
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLLS
Is CLLS getting ready to pop? NR7 shows up after climbing 2.6%
12 Health Care Stocks Moving In Friday's Pre-Market Session
Is CLLS primed for upward momentum? Upper Bollinger Band Walk shows up after sliding 2.53%
Is CLLS gaining bullish strength? New 52 Week Closing High shows up after rallying 5.69%
Is CLLS gaining bullish strength? New Uptrend shows up after gaining 3.46%